Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Design of the tocilizumab in giant cell arteritis trial.

Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R, Zwerina J, Harari O, Stone JH.

Int J Rheumatol. 2013;2013:912562. doi: 10.1155/2013/912562. Epub 2013 Apr 7.

2.

Trial of Tocilizumab in Giant-Cell Arteritis.

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N.

N Engl J Med. 2017 Jul 27;377(4):317-328. doi: 10.1056/NEJMoa1613849.

PMID:
28745999
3.

A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).

Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, Paget SA.

Clin Exp Rheumatol. 2001 Sep-Oct;19(5):495-501.

PMID:
11579707
4.

Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.

Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puéchal X, Maurier F, de Wazieres B, Quéméneur T, Ravaud P, Mariette X.

Ann Rheum Dis. 2014 Dec;73(12):2074-81. doi: 10.1136/annrheumdis-2013-203586. Epub 2013 Jul 29.

PMID:
23897775
5.

Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.

Loricera J, Blanco R, Hernández JL, Castañeda S, Mera A, Pérez-Pampín E, Peiró E, Humbría A, Calvo-Alén J, Aurrecoechea E, Narváez J, Sánchez-Andrade A, Vela P, Díez E, Mata C, Lluch P, Moll C, Hernández Í, Calvo-Río V, Ortiz-Sanjuán F, González-Vela C, Pina T, González-Gay MÁ.

Semin Arthritis Rheum. 2015 Jun;44(6):717-23. doi: 10.1016/j.semarthrit.2014.12.005. Epub 2014 Dec 27.

PMID:
25697557
6.

Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.

Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, Stone JR, Stone JH.

Arthritis Care Res (Hoboken). 2012 Nov;64(11):1720-9. doi: 10.1002/acr.21750.

8.

A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.

Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA; Vasculitis Clinical Research Consortium.

Arthritis Rheumatol. 2017 Apr;69(4):837-845. doi: 10.1002/art.40044. Epub 2017 Mar 3.

PMID:
28133925
9.

Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.

Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, Younge BR, Weyand CM, Goronzy JJ.

Arthritis Rheum. 2006 Oct;54(10):3310-8.

10.

Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.

Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernández-Gutiérrez B.

Ann Intern Med. 2001 Jan 16;134(2):106-14.

PMID:
11177313
11.

Development and implementation of a double-blind corticosteroid-tapering regimen for a clinical trial.

Collinson N, Tuckwell K, Habeck F, Chapman M, Klearman M, Stone JH.

Int J Rheumatol. 2015;2015:589841. doi: 10.1155/2015/589841. Epub 2015 Mar 24.

12.

A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.

Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, Cohen P, Calabrese LH, Dickler H, Merkel PA, Fortin P, Flynn JA, Locker GA, Easley KA, Schned E, Hunder GG, Sneller MC, Tuggle C, Swanson H, Hernández-Rodríguez J, Lopez-Soto A, Bork D, Hoffman DB, Kalunian K, Klashman D, Wilke WS, Scheetz RJ, Mandell BF, Fessler BJ, Kosmorsky G, Prayson R, Luqmani RA, Nuki G, McRorie E, Sherrer Y, Baca S, Walsh B, Ferland D, Soubrier M, Choi HK, Gross W, Segal AM, Ludivico C, Puechal X; International Network for the Study of Systemic Vasculitides.

Arthritis Rheum. 2002 May;46(5):1309-18.

13.

[The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].

Shi Q, Zhao Y, Bao CD, Li XF, Huang F, Zhu P, Li ZG, Gu JR, Zhang ZY, Zhao DB, Zhao SL, Jiang QD, Tian J, Zhang FC.

Zhonghua Nei Ke Za Zhi. 2013 Apr;52(4):323-9. Chinese.

PMID:
23925361
14.

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis.

Evans J, Steel L, Borg F, Dasgupta B.

RMD Open. 2016 Jan 11;2(1):e000137. doi: 10.1136/rmdopen-2015-000137. eCollection 2016.

15.

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).

Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga TW.

Ann Rheum Dis. 2013 Jan;72(1):43-50. doi: 10.1136/annrheumdis-2011-201282. Epub 2012 May 5.

16.

Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.

Régent A, Redeker S, Deroux A, Kieffer P, Ly KH, Dougados M, Liozon E, Larroche C, Guillevin L, Bouillet L, Espitia O, Costedoat-Chalumeau N, Soubrier M, Brihaye B, Lifermann F, Lefevre G, Puéchal X, Mouthon L, Toussirot E; French Vasculitis Group, the Groupe Francais pour l’Etude de l’Artérite à Cellules Géantes, and the Club Rhumatismes et Inflammation.

J Rheumatol. 2016 Aug;43(8):1547-52. doi: 10.3899/jrheum.151252. Epub 2016 May 15.

PMID:
27182063
17.

Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients with Non-Infectious Uveitis.

Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, Hanout M, Hassan M, Afridi R, Agarwal A, Halim MS, Do DV, Nguyen QD.

Am J Ophthalmol. 2017 Sep 5. pii: S0002-9394(17)30373-2. doi: 10.1016/j.ajo.2017.08.019. [Epub ahead of print]

PMID:
28887113
18.

Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.

Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU; Infliximab-GCA Study Group.

Ann Intern Med. 2007 May 1;146(9):621-30.

PMID:
17470830
19.

Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?

van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW.

Ann Rheum Dis. 1996 Apr;55(4):218-23. Erratum in: Ann Rheum Dis 1996 Aug;55(8):563.

20.

Tocilizumab in refractory aortitis: study on 16 patients and literature review.

Loricera J, Blanco R, Castañeda S, Humbría A, Ortego-Centeno N, Narváez J, Mata C, Melchor S, Aurrecoechea E, Calvo-Alén J, Lluch P, Moll C, Mínguez M, Herrero-Beaumont G, Bravo B, Rubio E, Freire M, Peiró E, González-Vela C, Rueda-Gotor J, Pina T, Palmou-Fontana N, Calvo-Río V, Ortiz-Sanjuán F, González-Gay MÁ.

Clin Exp Rheumatol. 2014 May-Jun;32(3 Suppl 82):S79-89. Epub 2014 May 15.

PMID:
24854377

Supplemental Content

Support Center